Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02928978 · ClinicalTrials.gov registry record · Phase 2
Ruxolitinib for Premalignant Breast Disease
A Phase 2 study of Ductal Carcinoma In Situ and Atypical Ductal Hyperplasia, sponsored by Julie Nangia.
- Active
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 8
- Study locations
NCT02928978: Active Phase 2 study of Ductal Carcinoma In Situ and Atypical Ductal Hyperplasia, sponsored by Julie Nangia.
NCT02928978 is a Phase 2 study of Ductal Carcinoma In Situ and Atypical Ductal Hyperplasia that is active but no longer recruiting, run by Julie Nangia. The registered enrollment target is 100 participants, below the 251-participant average among 15 other Ductal Carcinoma In Situ trials with a reported enrollment target (60% lower). The trial reports 8 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02928978, a Phase 2 study of Ductal Carcinoma In Situ and Atypical Ductal Hyperplasia, is active but no longer recruiting, sponsored by Julie Nangia.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 8
- Study locations
Study Summary
This study is evaluating how ruxolitinib affects premalignant breast cells. One half of the study participants will receive ruxolitinib for approximately 15 days, and the other half will receive a placebo (sugar pill) for approximately 15 days. Once study participants have completed their ruxolitinib or placebo, participants will undergo surgery to remove the premalignant breast tissue.
Primary Outcome
The number of premalignant breast cells in apoptosis at the time of diagnosis will be compared to the number of cells in apoptosis following treatment with 15 (+/- 5) days of ruxolitinib or placebo.
Conditions Studied
Interventions
- DRUG Ruxolitinib
- DRUG Placebo (for Ruxolitinib)
Study Locations (8)
Texas
- University of Texas MD Anderson Cancer Center - Houston
- Harris Health System - Smith Clinic - Houston
- O'Quinn Medical Tower - McNair Campus; Dan L Duncan Comprehensive Cancer Center - Houston
Alabama
- University of Alabama at Birmingham - Birmingham
Indiana
- Indiana University Melvin and Bren Simon Cancer Center - Indianapolis
New York
- Montefiore Medical Center - The Bronx
North Carolina
- University of North Carolina at Chapel Hill - Chapel Hill
Tennessee
- Vanderbilt-Ingram Cancer Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2018-05-13 |
| Est. Completion | 2026-06 |
| Phase | Phase 2 |
What the registry record for NCT02928978 still lists
NCT02928978 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 251-participant average among 15 other Ductal Carcinoma In Situ trials with a reported enrollment target (60% lower).
The record links to 4 conditions, with Ductal Carcinoma In Situ appearing as the primary indexed condition, and to 2 interventions - of which Ruxolitinib is the first listed.
NCT02928978 lists 8 locations in 6 states (Texas, Alabama, Indiana).
Frequently Asked Questions
What is clinical trial NCT02928978 about?
NCT02928978 is a clinical study titled "Ruxolitinib for Premalignant Breast Disease". This study is evaluating how ruxolitinib affects premalignant breast cells. One half of the study participants will receive ruxolitinib for approximately 15 days, and the other half will receive a placebo (sugar pill) for approximately 15 days. Once study participants have completed their ruxolitini...
What is the current status of trial NCT02928978?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2018-05-13. Estimated completion is 2026-06.
What conditions does trial NCT02928978 study?
This clinical trial studies the following conditions: Ductal Carcinoma In Situ, Atypical Ductal Hyperplasia, Atypical Lobular Hyperplasia, Lobular Carcinoma In Situ.
What interventions are being tested in trial NCT02928978?
The interventions under investigation include: Ruxolitinib (DRUG), Placebo (for Ruxolitinib) (DRUG).
Who is sponsoring clinical trial NCT02928978?
This trial is sponsored by Julie Nangia, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02928978 being conducted?
This trial has 8 study locations across Alabama, Indiana, New York, North Carolina, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ductal Carcinoma In Situ
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02928978's enrollment target sits among peer trials
100 8th of 15 higher than 8 of 15 other Ductal Carcinoma In Situ trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ductal Carcinoma In Situ trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment
RECRUITING · Phase 2
-
Ultra Hypo-fractionated Adjuvant Whole Breast Radiation Therapy With Simultaneous Integrated Boost for Early-Stage Breast Cancer (H-ASSIST)
RECRUITING · Phase 2
-
EXploring Inflammation and Social deTerminants Study in Breast Cancer Patients
RECRUITING
-
Cryoablation as a Minimally Invasive Alternative to Surgery for Managing Ductal Carcinoma In Situ
RECRUITING · NA
-
A Study of Disappearing Markers for Daily Radiation Treatment Delivery for Breast Cancer Patients.
RECRUITING · NA
-
Novel Cavity Marking Technique in Breast Cancer Patients Undergoing Breast Conservation Surgery With Oncoplastic Reconstruction for the Delivery of Adjuvant Radiotherapy and Accuracy of Recommended Re-excisions
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI